Implementing HIV PrEP in Routine Practice

Jarrett Sell, MD, FAAFP, AAHIVS,
Penn State Health Hershey Medical Center, Hershey, Pennsylvania

American Family Physician. 2023;108(3):227-228.

Author disclosure: No relevant financial relationships.

HIV continues to have an impact globally. An estimated 1.2 million people in the United States are living with HIV, and there are 38,000 new cases of HIV each year, which has not decreased in the past decade.1 This is despite the U.S. Food and Drug Administration's approval of oral tenofovir/emtricitabine (Truvada) in 2012 for pre-exposure prophylaxis (PrEP). It has been shown to be highly e˚ective for preventing HIV acquisition, with an overall relative risk of 0.46 compared with placebo and a lower relative risk of 0.27 in those with 70% or greater adherence.2 Accordingly, the U.S. Preventive Services Task Force (USPSTF) recommends that physicians o˚er PrEP to people at high risk of HIV acquisition (grade A recommendation).2,3 Recent approval of oral tenofovir alafenamide/emtricitabine (Descovy) and injectable cabotegravir (Apretude) has expanded options for HIV prevention.

The Centers for Disease Control and Prevention estimates that only 25% of the 1.2 million people who could have benefited from PrEP received it in 2020.4 The 2019 initiative, Ending the HIV Epidemic: A Plan for America, set a goal of reducing new infections in the United States by at least 90% by 2030; PrEP use by 50% of those at risk is a key component of this plan.1 Yet, prescribing rates remain low and are not adequately reaching populations at the greatest risk of HIV acquisition. Although Black and Hispanic patients are disproportionately a˚ected by HIV, they are less likely to be aware of or take PrEP compared with White men who have sex with men.5 Family physicians are ideally positioned to prevent HIV, improve access to PrEP, and address current health inequities.

One of the first steps in understanding the health needs of our patients is routinely asking for a detailed sexual history that is open and affirming.6 These conversations are opportunities to eliminate inaccurate assumptions about HIV transmission risk and combat continued stigma related to HIV, intravenous drug use, and various sexual practices. However, despite patients indicating a preference for their physicians to routinely initiate conversations about sexual health, studies show that patients bring up PrEP more often than their physicians.79 This may be due to the physician's lack of knowledge, discomfort, or biases regarding sexual practices and terminology, and may be mitigated by a self-assessment to identify specific knowledge deficits and implicit biases and training on current sexual terminiology.6 The sexual history of older and established patients, in particular, is more likely to not be consistently obtained or updated.7 Routinely asking brief, nonjudgmental, open-ended questions can help normalize inclusion of this important aspect of health.

Access to physicians who prescribe PrEP, the need for frequent visits, and cost can be significant barriers to PrEP.10 Fortunately, the USPSTF grade A recommendation necessitates insurance coverage of medication costs and associated laboratory testing and clinical services. The Centers for Disease Control and Prevention also provides resources for those who are uninsured or underinsured.11

Since the FDA approval of PrEP medications, a number of excellent resources on safe PrEP prescribing have been produced, including articles in American Family Physician.3,1218 In a recent survey of 134 primary care physicians, respondents self-reported high overall knowledge of PrEP, and most thought it was safe and e˚ective.9 However, respondents reported that they had less specific knowledge of adverse e˚ects, baseline laboratory testing, and ongoing laboratory safety monitoring, which are key pieces and potential barriers to PrEP implementation.

It is time to move beyond training and resources that focus solely on physician attitudes and knowledge and design system-level solutions to current inefficiencies and inequities in delivery of care. Potential solutions include electronic health record (EHR) tools, local champions, and community resources.

A recent study showed that an EHR order set was the most important facilitator for PrEP prescribing, and another study showed an increase in PrEP prescribing in primary care when an EHR template was combined with education.9,19 Because family physicians do not have enough hours in the day to address all the recommended preventive health services with patients, EHR templates and order sets can streamline guideline-based care and promote patient adherence and retention.20 Improved access to physician champions who guide PrEP initiation and handle more complex management and clinical pharmacists who track medication adherence and assist with medication counseling has also been proposed.9 In addition, identifying and collaborating with local organizations (e.g., LGBTQ+ centers, sexually transmitted infection testing sites, addiction treatment centers, after-school programs) that serve at-risk populations who do not routinely seek traditional medical services is key to addressing health inequity.

As we strive to end the HIV epidemic and implement the USPSTF recommendation to offer PrEP to all people who are at high risk of HIV acquisition, family physicians should consider how patients can best initiate and adhere to treatment. Once PrEP is started, we can anticipate barriers to adherence. For example, scheduled office visits in a busy physician practice may not be the preferred way to get laboratory tests and medication refills, particularly for young, healthy patients. At the first visit, it can be helpful to review local testing options, consider standing laboratory orders, determine frequency of office visits, and discuss the ways that patients can best communicate barriers to care or obtaining refills. What feasible, systems-based solutions might make a difference in your area to promote a patient-centered approach for the prevention and eradication of HIV?

Address correspondence to Jarrett Sell, MD, FAAFP, AAHIVS, at jsell@pennstatehealth.psu.edu. Reprints are not available from the author.

Author disclosure: No relevant financial relationships.

  1. 1.Harris NS, Johnson AS, Huang YA, et al. Vital signs: status of human immunodeficiency virus testing, viral suppression, and HIV preexposure prophylaxis—United States, 2013–2018. MMWR Morb Mortal Wkly Rep. 2019;68(48):1117-1123.
  2. 2.Chou R, Evans C, Hoverman A, et al. Preexposure prophylaxis for the prevention of HIV infection: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2019;321(22):2214-2230.
  3. 3.Preexposure prophylaxis for the prevention of HIV infection: recommendation statement. Am Fam Physician. 2019;100(10) ): online. Accessed July 22, 2023. https://www.aafp.org/pubs/afp/issues/2019/1115/od1.html
  4. 4.Centers for Disease Control and Prevention. Core indicators for monitoring the ending the HIV Epidemic Initiative (preliminary data): National HIV Surveillance System data reported through June 2021; and preexposure prophylaxis (PrEP) data reported through March 2021. HIV Surveillance Data Tables. 2021;2(4):1-28. Accessed July 22, 2023. https://www.cdc.gov/hiv/pdf/library/reports/surveillance-data-tables/vol-2-no-4/cdc-hiv-surveillance-tables-vol-2-no-4.pdf
  5. 5.Kanny D, Jeffries WL IV, Chapin-Bardales J, et al.; National HIV Behavioral Surveillance Study Group. Racial/ethnic disparities in HIV preexposure prophylaxis among men who have sex with men—23 urban areas, 2017. MMWR Morb Mortal Wkly Rep. 2019;68(37):801-806.
  6. 6.Savoy M, O'Gurek D, Brown-James A. Sexual health history: techniques and tips. Am Fam Physician. 2020;101(5):286-293.
  7. 7.Ryan KL, Arbuckle-Bernstein V, Smith G, et al. Let's talk about sex: a survey of patients' preferences when addressing sexual health concerns in a family medicine residency program office. Primer. 2018;2:23.
  8. 8.Skolnik AA, Bokhour BG, Gifford AL, et al. Roadblocks to PrEP: what medical records reveal about access to HIV pre-exposure prophylaxis. J Gen Intern Med. 2020;35(3):832-838.
  9. 9.Sell J, Chen R, Huber C, et al. Primary care provider HIV PrEP knowledge, attitudes, and prescribing habits: a cross-sectional survey of late adopters in rural and suburban practice. J Prim Care Community Health. 2023;14:21501319221147254.
  10. 10.Bonacci RA, Van Handel M, Huggins R, et al. Estimated uncovered costs for HIV preexposure prophylaxis in the US, 2018. Health Aff (Millwood). 2023;42(4):546-555.
  11. 11.Centers for Disease Control and Prevention. Paying for PrEP. Accessed February 15, 2023. https://www.cdc.gov/hiv/basics/prep/paying-for-prep/
  12. 12.Gandhi RT, Bedimo R, Hoy JF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA Panel. JAMA. 2023;329(1):63-84.
  13. 13.Centers for Disease Control and Prevention. US Public Health Service. preexposure prophylaxis for the prevention of HIV infection in the United States—2021 update: a clinical practice guideline. Accessed February 6, 2023. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf
  14. 14.Centers for Disease Control and Prevention. HIV Nexus clinician resources. HIV prevention. Accessed February 6, 2023. https://www.cdc.gov/hiv/clinicians/prevention/index.html
  15. 15.American Academy of HIV Medicine. PrEP guidelines and recommendations. Accessed February 6, 2023. https://education.aahivm.org/product_bundles/2470
  16. 16.National Clinician Consultation Center. PrEP: pre-exposure prophylaxis. Accessed February 14, 2023. https://nccc.ucsf.edu/clinician-consultation/prep-pre-exposure-prophylaxis/
  17. 17.Tracer H, Jasmin W. Screening for HIV infection and preexposure prophylaxis for the prevention of HIV infection. Am Fam Physician. 2019;100(10):637-638.
  18. 18.Kaufman B, Zehtabchi S. Tenofovir for prevention of HIV infection. Am Fam Physician. 2017;96(1) ): online. Accessed July 22, 2023. https://www.aafp.org/pubs/afp/issues/2017/0701/od1.html
  19. 19.Lumsden J, Dave AJ, Johnson C, et al. Improving access to pre-exposure prophylaxis for HIV prescribing in a primary care setting. BMJ Open Qual. 2022;11(2):e001749.
  20. 20.Porter J, Boyd C, Skandari MR, et al. Revisiting the time needed to provide adult primary care. J Gen Intern Med. 2023;38(1):147-155.

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.